Safely Reopening New York’s Art Venues in a Pandemic

On the Digital Threshold podcast, industry leaders will provide insights regarding how modern venues and facilities are reimagining the arrival experience – and how innovations are elevating that journey.

In this debut episode, three guests with firsthand experience in reopening New York City for business in the wake of the COVID-19 pandemic joined host Anil Chitkara for a discussion on what they’ve learned from that experience and how those lessons might help craft future-proof best practices at the intersection of venues and technology.

Keith Prewitt, Chief Security Officer at the Metropolitan Museum of Art, Lisa Schroeder, Director of Finance at Lincoln Center, and Thomas Slade, Senior Security Director at the American Museum of Natural History, help oversee institutions that account for about 16 million visitors during a typical year. That makes each extremely qualified to provide useful tips and strategies for engaging in a successful reopening.

The three venues were part of a cultural consortium of sorts that helped spread best practices and strategies that were working as the pandemic progressed.

“I think one thing we all feel in New York City is the strong sense of community,” Schroeder said. “We all want to places to open, and we all want to be safe. We take a lot of pride in that.”

While each individual space required its own unique strategy for adapting to the constraints of the pandemic, one thing was shared – a need for agility. Many venues didn’t expect the pandemic to linger as long as it has, and that required continuous work to remain flexible in the face of a shifting environment and regulatory pressure.

Specific technologies have also played a role, from thermal scanners and contact tracing methods to enhanced entrance screening and more. One of the most critical aspects, the trio said, was to thoroughly vet vendors who might have rushed to market to capitalize on the pandemic and uncertainty.

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More